Overview

The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism

Status:
Active, not recruiting

Trial end date:
2021-12-30

Target enrollment:

Participant gender:

Summary

Functional neuroimaging of alcoholism vulnerability: glutamate, reward, impulsivity, and Pavlovian-to-instrumental transfer (PIT), part II Saracatinib

Phase:

Phase 1

Details

Lead Sponsor:

Yale University

Treatments:

Saracatinib